Karyopharm Therapeutics Inc (NASDAQ: KPTI) stock closed at $7.48 on 9/23/25 after a major increase of 27.9%. Moreover, this advance was accompanied by exceptionally high trading volume at 293% of normal. The stock has been extremely weak relative to the market over the last nine months but has risen 19.5% during the last week.
Current PriceTarget Research Rating
Karyopharm Therapeutics is currently unrated.
Rating Review
The stock is currently unrated.
Be the first to comment